ARTV - Artiva Biotherapeutics Inc

11.3
-0.430   -3.805%

Share volume: 172,442
Last Updated: 04-23-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$11.73
-0.43
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 35%
Dept financing 26%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-15.61%
1 Month
116.06%
3 Months
141.45%
6 Months
108.87%
1 Year
361.22%
2 Year
-5.83%
Key data
Stock price
$11.30
P/E Ratio 
N/A
DAY RANGE
$10.95 - $12.00
EPS 
-$3.48
52 WEEK RANGE
$1.47 - $14.53
52 WEEK CHANGE
$357.49
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
24.717 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-22-2025
BETA 
1.11
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$608,633
AVERAGE 30 VOLUME 
$339,129
Company detail
CEO: Fred Aslan
Region: US
Website: www.artivabio.com
Employees: 0
IPO year: 2024
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our principal executive offices are located at 5505 Morehouse Drive, Suite 100, San Diego, California.

Recent news